[go: up one dir, main page]

PE20090712A1 - Moduladores de la gamma secretasa - Google Patents

Moduladores de la gamma secretasa

Info

Publication number
PE20090712A1
PE20090712A1 PE2008001683A PE2008001683A PE20090712A1 PE 20090712 A1 PE20090712 A1 PE 20090712A1 PE 2008001683 A PE2008001683 A PE 2008001683A PE 2008001683 A PE2008001683 A PE 2008001683A PE 20090712 A1 PE20090712 A1 PE 20090712A1
Authority
PE
Peru
Prior art keywords
gamma secretase
modulators
benzylidine
ona
imidazol
Prior art date
Application number
PE2008001683A
Other languages
English (en)
Inventor
Zhaoning Zhu
Brian A Mckittrick
William J Greenlee
Robert D Mazzola Jr
John P Caldwell
Chad E Bennett
Duane A Burnett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40157701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090712(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090712A1 publication Critical patent/PE20090712A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA (I), DONDE B ES H, ALCOXI, ALQUILO, =O, =S, ENTRE OTROS; W ES -C(O)-, -S(O)2-; X DE PREDERENCIA N; R1, R8, R9 Y R10 SON CADA UNO H, ALQUILO, ARILALQUIL-, CICLOALQUILALQUIL-, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (R)-3-(1-(4-FLOROFENIL)ETIL)-5-(3-METOXI-4-(4-METIL-1H-IMIDAZOL-1-IL)BENZILIDINA)-2-TIOXOIMIDAZOLIDIN-4-ONA; (R)-3-(1-(4-FLUOROFENIL)ETIL)-3-IMINO-5-(3-METOXI-4-(4-METIL-1H-IMIDAZOL-1-IL)BENZILIDINA)-2-IMIDAZOLIDIN-4-ONA; ENTRE OTROS. SE REFIERE TAMBIEN UN PROCEDIMIENTO DE PREPARACION, A UNA COMPOSICION FARMACEUTICA Y A UN METODO DE TRATAMIENTO. DICHOS COMPUESTOS SON MODULADORES DE GAMMA SECRETASA, UTILES EN EL TRATAMIENTO DE ENFERMEDAD DE ALZHEIMER, DETERIORO COGNITIVO LEVE, SINDROME DE DOWN, ENTRE OTROS
PE2008001683A 2007-09-28 2008-09-26 Moduladores de la gamma secretasa PE20090712A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97595907P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
PE20090712A1 true PE20090712A1 (es) 2009-06-20

Family

ID=40157701

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001683A PE20090712A1 (es) 2007-09-28 2008-09-26 Moduladores de la gamma secretasa

Country Status (11)

Country Link
US (1) US20100298381A1 (es)
EP (1) EP2205567A1 (es)
JP (1) JP2010540524A (es)
CN (1) CN101878202A (es)
AR (1) AR068636A1 (es)
CA (1) CA2700964A1 (es)
CL (1) CL2008002876A1 (es)
MX (1) MX2010003397A (es)
PE (1) PE20090712A1 (es)
TW (1) TW200914442A (es)
WO (1) WO2009045314A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
US20130065897A1 (en) * 2009-12-23 2013-03-14 Peter Maccallum Cancer Institute Compounds, preparation and uses thereof
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
JP6321685B2 (ja) 2013-02-25 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ２−アミノ−３，４−ジヒドロ−キナゾリン誘導体、およびそのカテプシンｄ阻害剤としての使用
CN107406445B (zh) 2015-02-03 2019-12-24 辉瑞公司 新颖环丙苯并呋喃基吡啶并吡嗪二酮类
CN105218457A (zh) * 2015-09-21 2016-01-06 山东大学 一种3,5,5’-三取代-2-乙内酰硫脲的制备方法
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308318D0 (en) * 2003-04-10 2003-05-14 Merck Sharp & Dohme Therapeutic agents
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
JP5221144B2 (ja) * 2005-11-24 2013-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 モルホリンタイプ・シンナミド化合物

Also Published As

Publication number Publication date
MX2010003397A (es) 2010-04-09
WO2009045314A1 (en) 2009-04-09
CA2700964A1 (en) 2009-04-09
JP2010540524A (ja) 2010-12-24
AR068636A1 (es) 2009-11-25
TW200914442A (en) 2009-04-01
US20100298381A1 (en) 2010-11-25
CL2008002876A1 (es) 2010-02-05
EP2205567A1 (en) 2010-07-14
CN101878202A (zh) 2010-11-03

Similar Documents

Publication Publication Date Title
PE20090712A1 (es) Moduladores de la gamma secretasa
PE20091095A1 (es) Moduladores de gamma secretasa
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20060401A1 (es) Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
PE20080997A1 (es) Compuestos n-fenilmetil-5-oxo-prolina-2-amida como moduladores de receptores p2x7
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20020084A1 (es) N-(glicilo sustituido)-2-ciano-pirrolidinas como inhibidores de la dipeptidilpeptidasa-iv
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
EA200601849A1 (ru) 4-фениламинохиназолин-6-ил-амиды
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
AR036906A1 (es) Compuestos de imidazopiridin como moduladores del receptor 5-ht4
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
PE20060679A1 (es) Cis-imidazolinas como inhibidoras de la interaccion de la proteina mdm2 y los polipeptidos similares al p53
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20080362A1 (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
TNSN08311A1 (en) Indole sulfonamide modulators of progesterone receptors
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas

Legal Events

Date Code Title Description
FD Application declared void or lapsed